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Abstract. – OBJECTIVE: NBOMe is a class of
emerging new psychoactive substances that
has recently gained prominence in the drug
abuse market. NBOMes are N-2-methoxy-benzyl
substituted 2C class of hallucinogens, currently
being marked online as “research chemicals”
under various names: N-bomb, Smiles, Solaris,
and Cimbi. This article reviews available litera-
ture on the pharmacology; the analytical meth-
ods currently used for the detection and quan-
tification of NBOMe in biological matrices and
blotters, together with intoxication cases and
NBOMe-related fatalities.
MATERIALS AND METHODS: Relevant sci-
entific articles were identified from Medline,
Cochrane Central, Scopus, Web of Science, Sci-
ence Direct, EMBASE and Google Scholar,
through June 2015 using the following key-
words: “NBOMe”, “Nbomb”, “Smiles”, “intoxica-
tion”, “toxicity” “fatalities”, “death”, “pharma-
cology”, “5-HT2A receptor”, “analysis” and “an-
alytical methods”. The main key word “NBOMe”
was individually searched in association to
each of the others.
RESULTS: The review of the literature allowed
us to identify 43 citations on pharmacology, an-
alytical methods and NBOMe-related toxicities
and fatalities.
CONCLUSIONS: The high potency of NBOMes
(potent agonists of 5-HT2A receptor) has led to
several severe intoxications, overdose and trau-
matic fatalities; thus, their increase raises signif-
icant public health concerns. Moreover, due to
the high potency and ease of synthesis, it is like-
ly that their recreational use will become more
widespread in the future. The publication of new
data, case reports and evaluation of the NBOMes
metabolites is necessary in order to improve
knowledge and awareness within the forensic
community.
Key Words:
NBOMe, N-Bomb, Pharmacology, Analytical meth-
ods, Intoxication, Fatalities.
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Introduction
The continual emergence of new psychoactive
substances (NPS) is a global issue. Designer
drugs, also referred to as bath salts and legal
highs1,2 include synthetic cannabinoids (Spice),
substituted cathinones (e.g., mephedrone, methy-
lone, and methylenedioxypyrovalerone (MDPV)
and synthetic hallucinogens (NBOMe, or N-
bomb)3. NBOMe class has recently entered the
drug scene and is considered to be the newest in
a series of designer drugs.
NBOMes are N-2-methoxy-benzyl substituted
2C class of hallucinogens, currently being
marked online as “research chemicals” under
various names N-bomb, Smiles, Solaris, and
Cimbi; originally synthesized for research pur-
poses as potent agonists of 5-hydroxytryptamine
receptor subtype 2A (5-HT2A)4. The 2C hallu-
cinogens (for example: 2C-B, 2C-I, etc.) are
phenylethylamines with methoxy group (OCH3
or OMe) substitutions at the 2- and 5-positions5,
that possess structure similarities with MDMA
and mescaline, causing physical and psychologi-
cal effects and hallucinations through serotoner-
gic stimulation. The “2C” series of hallucino-
genic phenethylamines were first described by
Alexander and Anne Shulgin6 who used the term
“2C” which refers to the two carbons between
the benzene ring and the amino group. Chemical
structures of phenethylamine, 2C-phenethy-
lamine, 2 C-C and N-(2-methoxybenzyl)-2,5-
dimethoxy-4-chlorophenethylamine (25C-
NBOMe) are given in Figure 1.
U.S. Drug Enforcement Administration (DEA)
ordered an issue to temporary schedule many of
the compounds marketed as bath salts in Sched-
ule I status, in October 2011. However, Illicit
drug designers have demonstrated considerable
2015; 19: 3270-3281
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Iodophenethylamine (25I-NBOMe), 25C-
NBOMe and 25H-NBOMe.
Substances of NBOMe-class have a high affin-
ity at the 5-HT2A receptor10, thus sublingual sub-
milligram doses may lead to threshold effects8,11.
Their effects are likely to be similar to the lyser-
gic acid diethylamide (LSD) and 2C hallucino-
gens ie. euphoria, hallucinations, powerful visual
and sensory effects, unusual body sensations,
mystical experiences, empathic feelings and al-
terations in consciousness11,12.
Between 2012 and 2013 25 NBOMe expo-
sures were reported to Texas poison centers
(USA), 76% involved 25I-NBOMe, 12% 25C-
NBOMe, and 12% an unknown NBOMe. The
majority (88%) of patients were men and mean
age was 17 years (range: 14-25 years)13.
Currently, the most widely used NBOMe sub-
stances are 25I-NBOMe (street names: 25I, INB-
MeO, N-bomb, Smiles, Solaris and Cimbi-5), fol-
lowed by N-(2-methoxybenzyl)-2,5-dimethoxy-4-
bromophenethylamine (25B-NBOMe) and 25C-
NBOMe (street names C-Boom, Cimbi-82, Pan-
flexibility in modifying the psychoactive part of
designer drugs, which leads to new unscheduled
drugs, in order to evade both the legal restriction
and detection through analytical methods2,7.
The NBOMe series has practically no history of
human consumption prior to 2010 when they first
became available on the internet8. Blotter papers
and powders containing psychedelics appeared on
the Polish drug market in 2011 and new phenethy-
lamine derivatives were detected in the Institute of
Forensic Research (IFR) in Krakow (Poland).
Among others, three representatives of the
NBOMe compounds containing alkyl group at po-
sition 4 of the benzyl ring9 were identified first.
Blotter papers impregnated with 25C-NBOMe al-
so entered the market in 2011, and nowadays this
drug can usually be found in online shops.
Exemplary blotter papers impregnated with
NBOMe compounds that have been analyzed in
the State General Laboratory of Cyprus after be-
ing seized by the police are presented in Figure
2. The blotters were found to contain a mixture
of N-(2-methoxybenzyl)-2,5-dimethoxy-4-
Figure 1. Chemical structures of phenethylamine, 2C-phenethylamine, 2 C-C and 25C-NBOMe.
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to insufflation14. Clinical effects are displayed
rapidly after nasal administration and reach a
peak 20 minutes after intake. Effects are reported
to be similar to those of psilocybin or LSD3. Ac-
cording to users, hallucinations, stimulating ef-
fects and depersonalization are displayed after14.
25C-NBOMe appears to be active at a dose of
200-1000 µg when taken sublingually or in-
tranasally, while doses between 50 and 500 µg
when smoked have been reported by users. Light,
mild, strong, and very strong effects have been
reported after insufflation of 50-200, 200-350,
350-700 and > 700 µg of 25C-NBOMe, respec-
tively. When administered sublingually, the
threshold effect is displayed after a dose of 100-
250 µg while mild, strong and very strong effects
are achieved following 250-450, 450-800 and
over 800 µg doses, respectively. Total duration of
action can last from 4 to 10 hours8.
Even though NBOMes have only been avail-
able for a short time, many adverse effects like
severe intoxications, traumatic deaths and fatal
overdoses have already been documented in case
reports. In this paper we aim to review the litera-
ture regarding this potent group of NPS and pre-
sent the available information in pharmacology,
even though it is limited and is mostly related to
the affinity of this potent group of drugs with the
5-HT2A receptor. Analytical methods for the de-
tection and quantification of NBOMes either in
biological samples or blotter papers, analytically
confirmed intoxications and NBOMe related fa-
talities are also presented.
Materials and Methods
Relevant scientific articles were identified
from Medline, Cochrane Central, Scopus, Web of
dora and Dime8,14). Nevertheless, several other
drugs belonging to NBOMe class have been indi-
cated in the literature including 2-(2,5-
d i m e t h o x y - 4 - m e t h y l p h e n y l ) - N - ( 2 -
methoxybenzyl) ethanamine (25D-NBOMe), 2-
( 4 - e t hy l - 2 , 5 - d ime t h oxyph eny l ) -N - ( 2 -
methoxybenzyl) ethanamine (25E-NBOMe), 2-
(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2-
methoxybenzyl)ethanamine (25G-NBOMe), 2-
(4 - iodo-2 ,5-d imethoxyphenyl ) -N-[ (2 ,3-
methylenedioxyphenyl)methyl]ethanamine (25I-
NBMD), 25H-NBOMe, 25I-NBF, 25T4-NBOMe,
2CT-NBOMe, 2CBFly-NBOMe, 2CBCB-
NBOMe, 25T7-NBOMe, 25TFM-NBOMe, 25T2-
NBOMe, 25N-NBOMe and 25P-NBOMe4,15,16.
They are most commonly sold on blotter paper,
but they are also available in powder. NBOMe
compounds are similarly marketed to LSD i.e. on
blotter papers decorated with various artwork pat-
terns. Because of the decreased availability of
LSD in recent years, NBOMes are reportedly be-
ing sold as LSD or marketed as a “legal LSD”8,11.
25I-NBOMe is available in both powder and
liquid form and different ways of intake have
been reported including ‘sniffing’, vapor inhala-
tion, oral and intravenous ingestion, while the
most common form of administration is sublin-
gual/buccal5,14. Pill ingestion and absorption
through oral mucosal route of either the powder
form or blotter papers impregnated with the drug
has also been reported. It appears to be active at
low doses (50-250 µg) and a typical dose ranges
from 500 to 800 µg. Anecdotal reports indicate
that NBOMes are highly potent when taken sub-
lingually, buccally, or insufflated, but have very
low oral bioavailability. Activity time length from
3 to 13 hours has been reported, depending on the
route of administration, with the action lasting
longer after sublingual administration compared
Figure 2. Blotter sheets presenting 3 different artwork patterns containing a mixture of 25I-NBOMe, 25C-NBOMe and 25H-
NBOMe. The first (on the left) has dimensions of 19 × 19 cm and is consisted of 900 blotter papers, while the second (in the
middle) has dimensions of 6.5 × 6.5 cm and is consisted of 100 blotters. The one on the right is a fragment of a bigger blotter
sheet of original size of 19 × 19 cm (900 blotters). Each blotter paper has dimensions of 0.65 × 0.65 cm.
Science, Science Direct, EMBASE and Google
Scholar, through June 2015 using the following
keywords: “NBOMe”, “Nbomb”, “Smiles”, “in-
toxication”, “toxicity” “fatalities”, “death”,
“pharmacology”, “5-HT2A receptor”, “analysis”
and “analytical methods”. The main key word
“NBOMe” was individually searched in associa-
tion to each of the others.
Results
The review of the literature allowed us to iden-
tify 43 citations3-6,8-46 on pharmacology, analyti-
cal methods and NBOMe-related toxicities and
fatalities. The findings are below discussed.
Pharmacology
There is limited information on pharmacologi-
cal data concerning NBOMe series. Psychophar-
macology (i.e. effects on consciousness and hal-
lucinations) of psychedelic substances including
LSD is attributed to the agonist action on the
serotonin 5-HT2A receptor9,17. The 5-HT2A recep-
tor has been associated with complex behaviors
including cognitive processes and working mem-
ory and it is also involved in the pathophysiology
of affective disorders such as schizophrenia and
depression.
Structure-activity relationship (SAR) studies
have led to substances with low nanomolar
affinities for this specific receptor, some of which
are among the most potent partial agonists with
hallucinogenic effects known to date18-21. Data
suggest that drugs of 2C-class interact effectively
with serotonin receptors, most of which act as 5-
HT2A receptor agonists. Typically, a 2C-class
substance carries a lipophilic substituent in the
para position (relative to the side chain), which
contributes to further enhance 5-HT2A affinity
and partial agonistic action22,23. The most active
compounds identified to date possess an ether,
alkylthio, alkyl, or halogen group at this position
and their potency increases in the aforemen-
tioned sequence24,25. The results retrieved from
SAR studies suggest that N-substitution of com-
mon phenethylamines with short alkyl sub-
stituents (methyl or ethyl groups) considerably
decreases the binding affinity for serotonin re-
ceptors compared to the unmodified compounds.
However, the addition of an N-benzyl moiety in-
creases the affinity and potency4. Braden et al26
illustrated this by adding an N-benzyl group to
2,5-dimethoxy-b-phenethylamine (2C-H); the
binding affinity increases 13-times26. The addi-
tion of an N-(2-methoxy) benzyl, or N-(2-
hydroxy) benzyl, group to 2C-H led to 190- and
82-fold increases in affinity, respectively. More-
over, the latter substances displayed high selec-
tivity (> 1000-fold) for 5-HT2A receptors over 5-
HT1A and moderate selectivity (up to 35-fold)
for 5-HT2A over 5-HT2C.
Subsequently, Silva et al27 studied a series of
51 arylethylamines (indoles, methoxybenzenes,
and quinazolinediones), partial agonists of 5-
HT2A and concluded that among the substituents
at the amino nitrogen, a 2-methoxybenzyl group
was the most favorable.
Heim28 was the first to investigate the pharma-
cological properties of NBOMe-series. 25C-
NBOMe acts as a potent 5-HT2A receptor’s par-
tial agonist. 11C radiolabeled form of 25C-
NBOMe has been studied as a potential ligand to
map the distribution of 5-HT2A receptors in the
brain by positron emission tomography (PET)15.
This drug has a nanomolar affinity to the 5-HT2A
receptor displaying an agonistic binding affinity
of 2.89 ± 1.05 nM in vitro15 thus it has been char-
acterized as “superpotent” by Braden et al4. It is
pharmacologically active even at considerably
small submilligram doses8.
Moreover, Halberstadt and Geyer10 studied the
effects of 25I-NBOMe on the head twitch re-
sponse (HTR) that is induced by activation of 5-
HT2A receptor in rats and mice and is widely
used as a behavioral proxy for hallucinogen ef-
fects in humans. 25I-NBOMe displayed 14-fold
higher potency than 2C-I. The findings suggest
that phenethylamine hallucinogens induce the
HTR by activating 5-HT2A receptors and that 25I-
NBOMe is a highly potent derivative of 2C-I,
which is in accordance to previous in vitro find-
ings suggesting that N-benzyl substitution in-
creases 5-HT2A affinity.
Presently, there is limited information regard-
ing the metabolic pathways of NBOMe com-
pounds. Stellpflug et al29 analyzed a urine sam-
ple, collected from a 25I-NBOMe intoxicated
subject, in order to establish the metabolism of
the drug by identifying excreted metabolites. The
sample was collected approximately 3 h after ex-
posure to the drug. At that point, unchanged 25I-
NBOMe was detected along with a single
demethylated metabolite that was found at a level
approximately 80-fold higher than the parent
drug. Another demethylated product was also de-
tected at levels similar to those of the unchanged
compound. All of the demethylated metabolites
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were found to be excreted exclusively as glu-
curonide conjugates. 25H-NBOMe and 2C-I
were also detected, although their use was not re-
ported. More likely, 25H-NBOMe was present as
a contaminant in the ingested drug formulation.
The presence of 2C-I could be explained as 25I-
NBOMe is most commonly synthesized by the
reductive coupling of methoxybenzaldehyde with
2C-I or 2C-I could result from metabolic cleav-
age of 25I-NBOMe at the amine within the chain
linking of the two ring structures.
Analytical Methods
Although laboratory testing is expanding in or-
der to include the so called new designer dugs,
widespread standardized testing targeting these
drugs is not yet available in most forensic and
clinical toxicology laboratories. A number of
methods to identify and quantify NBOMe com-
pounds in biological specimens have been report-
ed in literature. The most commonly reported
chromatographic separation techniques for this
purpose is either high performance liquid chro-
matography (HPLC) or ultra-performance liquid
chromatography (UPLC) coupled to either tan-
dem mass spectrometry (MS-MS) or high-resolu-
tion time-of-flight mass spectrometry (HRTOF–
MS). As extraction procedure both liquid-liquid
extraction (LLE) and solid phase extraction
(SPE) have been stated. Poklis et al30 developed a
HPLC/MS/MS method for the identification and
quantification of 25I-NBOMe and 2CC-NBOMe
in the serum of intoxicated subjects. The samples
were extracted using SPE technique and 25H-
NBOMe was used as internal standard. In a sub-
sequent study31 a HPLC–MS-MS method for the
detection and quantification of nine NBOMe
compounds in urine (25H-NBOMe, 25C-
NBOMe, 25I-NBF, 25D-NBOMe, 25B-NBOMe,
2CT-NBOMe, 25I-NBMD, 25G-NBOMe and
25I-NBOMe) using a rapid SPE was developed.
Moreover, HPLC-MS/MS method for the identi-
fication and quantification of 25B-NBOMe in
serum and urine, after a simple LLE technique
using 25H-NBOMe as the internal standard was
developed and then applied in a severe intoxica-
tion case32.
Identification of 25C-NBOMe and a demethy-
lated and glucuronidated metabolite of 25C-
NBOMe in urine and blood samples was
achieved by using UPLC–HRTOF–MS, while
quantification of this potent drug in post-mortem
specimens (peripheral whole blood, urine, vitre-
ous humor, liver, and gastric content) and in ante-
mortem whole blood sample was performed by
UPLC–MS/MS33. Stellpflug et al29 used LC-
MS/MS for the quantification of 25I-NBOMe
and UPLC–TOF-MS for the identification of ex-
creted metabolites of the same drug in urine sam-
ples collected from a clinical case. Pasin et al34
developed and validated a method for the detec-
tion and identification of 37 new designer drugs,
including 25B-NBOMe, 25C-NBOMe, 25H-
NBOMe and 25I-NBOMe, in whole blood using
LC–QTOF-MS.
Blotter paper is among the most common
means of administration of the so called NBOMe
compounds. Forensic analysis of blotters is nor-
mally performed by GC–MS or LC–MS8,35. The
latest techniques require a sample preparation,
including extraction of analytes by soaking blot-
ters in organic solvents, filtration and/or dilution,
prior to injection which, however, is considered
to be time consuming and sample-destructive.
Coelho36 reported a method that rapidly detects
NBOMes and other NPS by taking ATR-FTIR
spectra directly from the blotters. In 39 blotter
papers tested (out of 77) three types of NBOMe
class (25B-NBOME, 25C-NBOME and 25I-
NBOME) were detected. This analysis should
only be considered as a quick preliminary test
since each blotter is a mixture of paper and one
or more NPS, which reduces the discriminating
power of IR spectrometry, therefore confirmation
with analytical techniques such as GC–MS or
LC–MS is still necessary.
NBOMe Related Toxicities
NBOMe series have been implicated in severe
clinical intoxications, with patients commonly
displaying serotonergic and sympathomimetic
symptoms. Such intoxications have been reported
not only in media37 and internet forums but also
in scientific literature, providing information on
the effects produced after the administration of
these potent compounds and the concentrations
in biological fluids. A comprehensive review by
Suzuki et al38 has recently been published,
putting together the published reports of
NBOMe-linked toxicities, providing demograph-
ic and clinical data and information on adverse
effects. However, here emphasis is given to the
circumstances of each case separately and the
concentrations found in biological samples.
Suzuki et al11 reported a case of attempted
suicide after 25I-NBOMe ingestion. An 18
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year-old male had sublingually taken two “blot-
ters” claimed to be “good LSD”. One hour after
the ingestion he began to experience euphoria,
tachycardia, and visual hallucinations. After
several hours the drug effects continued to in-
crease in intensity and the man displayed anx-
iousness and confusion. Then feeling trapped,
he became anxious and began to panic; in order
to end this experience he attempted to commit
suicide using a pair of scissors stabbing himself
in the neck and chest. When he realized the ex-
tent of his injuries, approximately 11 hours af-
ter drug intake he called the emergency ser-
vices. His symptoms were treated at the emer-
gency unit and he was sent to the operating
room for wound exploration and closure. Three
days after admission, he was transferred to a
psychiatric facility for continued treatment and
was finally discharged a week later.
Hill et al39 described the effects produced in 7
young adult males after analytically confirmed
recreational use of 25I-NBOMe in the United
Kingdom. Tachycardia and elevated creatine ki-
nase were displayed in all 7 cases, while 6 out of
7 patients showed agitation, aggression, visual
and auditory hallucinations. Hypertension was
noticed in 4 subjects, while in 3 cases the clinical
features included seizures, hyperpyrexia and
metabolic acidosis. Clonus and elevated white
cell count were noticed in 2 individuals while in
one case there was acute kidney injury. The au-
thors concluded that severe clinical toxicity may
occur after recreational intake of this potent drug,
with serotoninergic and stimulant features pre-
dominating.
According to Rose et al40, an 18-year-old male
was suffering with severe agitation, hallucina-
tions, tachycardia and hypertension. Serum sam-
ple, collected during emergency department eval-
uation, was found to contain 0.76 ng/ml of 25I-
NBOMe. Although, the patient’s symptoms grad-
ually improved leading him to recover over a pe-
riod of 48 hours, he continued to suffer from
episodes of aggressiveness. Another case involv-
ing an 18-year-old female with tachycardia, agi-
tation, hypertension, confusion and seizure is de-
scribed by Stellpflug et al29. In this case the 25I-
NBOMe urine level was 7.5 ng/mL and 25H-
NBOMe was also detected. She improved after
benzodiazepine administration and was dis-
charged 7 hours post-ingestion29. Poklis et al30 re-
ported two severely intoxicated cases with serum
25I-NBOMe concentrations of 250 and 2780
pg/mL.
A 19-year-old man was in danger of dying af-
ter nasal intake of 2 mg of 25C-NBOMe. Two
hours after administration, he experienced a gen-
eralized seizure, loss of consciousness and low
oxygen saturation thus mechanical ventilation
was required. On day 2, he appeared to recover
quickly but he developed acute kidney failure re-
quiring hemofiltration on the third day. Acute
lung failure developed on day 4, while on days 7
and 8 his condition became life threatening due
to insufficient oxygenation. Finally he fully re-
covered after 13 days in the intensive care unit41.
A 24-year-old female, after analytically con-
firmed ingestion of 3 blotters containing 25C-
NBOMe and a smaller amount of 25I-NBOMe
had the following symptoms: tachycardia,
tachypnea, agitated delirium, confusion, impres-
sion of being attacked, dilated pupils and disori-
entation35.
A serum and urine 25B-NBOMe concentra-
tions of 180 pg/ml and 1900 pg/ml, respectively
were determined after a 19-year-old male was
found unresponsive with generalized grand mal
seizure activity, following the administration of
an unknown drug, called 25B32. In another two
cases reported by Tang et al42 two male patients
of 17 and 31 years displayed the same features as
above described by Rose et al40, following an in-
gestion of drugs labelled as ‘NBOMe’, together
with confusion, hyperthermia, sweating, dilated
pupils, convulsion, rhabdomyolysis and deranged
liver function. 25B-NBOMe was identified in
both urine samples, whereas 25C-NBOMe was
detected in one of the urine samples.
Table I illustrates the NBOMe concentrations
found in patients suffering from toxicity after in-
take of NBOMe compounds together with the
route of administration, product and dose con-
sumed and other toxicological findings. In this
table only those reports providing quantification
of NBOMe substances in biological samples,
have been included11,29,32,40,43.
NBOMe Related Deaths
NBOMe compounds, although only recently
encountered in the drug market, have already
been associated with a number of fatalities main-
ly reported in the so-called grey literature, in-
cluding personal drug experience websites, news-
papers and internet forums. However, only four
papers, representing 5 cases, have been published
providing information on analytically confirmed
NBOMe-related deaths33,44-46. The findings of
these 4 papers are here provided.
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Poklis et al44 presented a traumatic fatality of a
young (19 years-old) man who had ingested blot-
ter paper containing 25I-NBOMe. After ingestion
this man displayed paranoid behavior and he was
finally found by his friends unresponsive on the
pavement near the apartment complex swimming
pool. It is believed that the deceased had either
jumped or had fallen from his balcony located
multiple floors above where he was found. It is
worth pointing out that although the decedent
had ingested the same drug as his friends, he was
the only one to display bizarre behavior, proba-
bly because this was the first time he had ingest-
ed a hallucinogenic drug.
Toxicological analysis of biological fluids
and tissues retrieved the following results: pe-
ripheral blood, heart blood, urine, vitreous hu-
mor, gastric contents, bile, brain and liver 405
pg/mL, 410 pg/mL, 2.86 ng/mL, 99 pg/mL, 7.1
µg total, 10.9 ng/g, 2.54 ng/g and 7.2 ng/g, re-
spectively.
Since the urine and blood concentrations
found in this postmortem case fall within the
range of values of the 25I-NBOMe intoxicated
patients reported in literature, authors assume
that the deceased was suffering from mental
confusion and/or delusional thoughts and/or
hallucinations which possibly contributed to his
fall, whether intentional, i.e. commit suicide or
attempt to fly, or accidental44.
Kueppers and Cooke45 reported a fatal case
where three NBOMe compounds were detected
in the post mortem aortic non-preserved blood
and urine. The deceased (23 year-old woman)
was witnessed sniffing an unknown white pow-
der. After nasal intake she demonstrated strange
behavior, agitation and began uttering random
words, shouting, and eventually started thrashing
about aggressively. After going into a seizure and
vomiting she collapsed and was pronounced
dead.
25I-NBOMe, 25H-NBOMe and 25C-NBOMe
were present in post-mortem blood at approxi-
mate concentrations of 28, 1 and 0.7 µg/L, re-
spectively. In this case the level of 25I-NBOMe
found in blood appears to be much higher than
that previously reported in intoxicated patients
and analytically confirmed 25I-NBOMe-linked
fatalities. Moreover, methylamphetamine (0.39
mg/L), tetrahydrocannabinol (3.4 µg/L) and a
small amount of promethazine were also detected
in the decedent’s blood thereby determining the
cause of death to be a combined drug toxicity in-
cluding 25I-NBOMe45.
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ported47. In contrast, despite the fact that
NBOMes have only recently entered the drug
market scene a number of severe intoxications
and deaths have been linked to this group. Thus,
medical and paramedical personnel are encour-
aged, when managing patients who present
symptoms of psychosis and are presumed to be
drug abusers or report recent use of LSD or other
hallucinogens, to consider the diagnosis of an in-
advertent NBOMe-type drug overdose therefore
taking all the necessary precautions needed37.
Results obtained by Coelho36 suggest great in-
homogeneity in drug dosages even within blot-
ters presenting the same artwork, taken from the
same blotter sheet. This could be attributed to the
fact that these drugs are produced in clandestine
labs by amateur cookers5. Taking into account
the potency of this class, the variation of purity
and the inhomogeneity in drug dosages users can
easily overdose.
Moreover, the high potency and small dose in-
gested makes analytical detection of NBOMes
exceedingly difficult. Even for laboratories with
highly sensitive methods the detection of these
hallucinogens is challenging, since the signals
from these drugs are very low and are easily lost
in the background noise of the sample. There-
fore, it is worth pointing out that it is of the up-
most importance for clinicians, forensic patholo-
gists and investigators in intoxication and fatal
cases to provide relevant information and circum-
stances of their cases to the toxicology laborato-
ry. Moreover, due to the lack of proper routine
analytical methods, the number of NBOMe relat-
ed intoxications and fatal cases may well be un-
derestimated.
Furthermore, although 3 representatives of this
potent class have been temporarily scheduled in
schedule 1 of the Controlled Substances Act by
DEA (Drug Enforcement Administration), fur-
ther legislative measures should be taken world-
wide since these drugs are only banned in some
countries.
Conclusions
Due to the high potency and ease of synthesis,
it is likely that the recreational use of NBOMe
will become more widespread in the future. The
publication of new data, case reports and evalua-
tion of the NBOMes metabolites is necessary in
order to improve knowledge and awareness with-
in the forensic community.
Andreasen et al33 reported a fatal overdose
case involving 25C-NBOMe. A young man pro-
nounced dead at hospital approximately 12h after
the recreational use of this compound. Both ante-
and post-mortem samples were collected and an-
alyzed. Analysis of ante-mortem whole blood,
collected at 2-4 hours after ingestion of the drug,
retrieved a 25C-NBOMe concentration of 0.81
µg/kg. In the post mortem samples, peripheral
whole blood, urine, vitreous humour, liver and
gastric content, the drug was found at the follow-
ing concentrations: 0.6, 2.93, 0.33, 0.82 µg/kg
and 0.32 µg total, respectively.
The cause of death was attributed to a fatal
overdose of 25C-NBOMe in combination with
amphetamine intake. Again, although the de-
ceased had sniffed the drug with a friend of his,
the friend displayed none of the symptoms that
the decedent had i.e. strange behavior, hallucina-
tions and jerky movements but he only reported
having “a good trip” for 4-6 h after ingesting the
25C-NBOMe33 .
Moreover, Walterscheid et al46 also cited 2
deaths after 25I-NBOMe ingestion, in both cases
the cause of death was attributed to fatal 25I-
NBOMe toxicity. However, no quantification re-
sults are given46.
A summary of the findings (both autopsy and
toxicological) of the four papers above described
is given in Table II.
Discussion
NBOMe is a novel dangerous group of hallu-
cinogenic drugs which has recently gained
prominence. Although this potent group of drugs
was first synthesized for scientific purposes as a
tool to study the 5-HT2A receptor, it is currently
used as a recreational drug. It can be assumed
that these pharmacological studies have attracted
the interest of clandestine designers of NPS.
The fact that this class of drugs is being coun-
terfeited as LSD raises significant health con-
cerns, since a recreational LSD user may con-
sume NBOMe unintentionally. In fact, both in se-
vere intoxications and fatal cases where the in-
gestion of NBOMe compounds was analytically
confirmed the individuals involved, incorrectly
thought they had consumed “acid”11,35,44,46. The
effects produced after the use of “traditional”
hallucinogens, including LSD, are treated with
the use of benzodiazepines. Moreover, no fatal
cases attributed to LSD overdose have been re-
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